Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study

INTRODUCTION: Pulmonary involvement represents a major cause of death of systemic sclerosis (SSc) patients. Recent data suggest that tyrosine kinase inhibitors, such as imatinib, may be a therapeutic option for SSc patients. However, preliminary published clinical trials were inconclusive about imat...

Descripción completa

Detalles Bibliográficos
Autores principales: Fraticelli, Paolo, Gabrielli, Barbara, Pomponio, Giovanni, Valentini, Gabriele, Bosello, Silvia, Riboldi, Piersandro, Gerosa, Maria, Faggioli, Paola, Giacomelli, Roberto, Del Papa, Nicoletta, Gerli, Roberto, Lunardi, Claudio, Bombardieri, Stefano, Malorni, Walter, Corvetta, Angelo, Moroncini, Gianluca, Gabrielli, Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227120/
https://www.ncbi.nlm.nih.gov/pubmed/25007944
http://dx.doi.org/10.1186/ar4606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227120/
https://www.ncbi.nlm.nih.gov/pubmed/25007944
http://dx.doi.org/10.1186/ar4606

Ejemplares similares